Cargando…
Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075856/ https://www.ncbi.nlm.nih.gov/pubmed/35533699 http://dx.doi.org/10.1016/S2213-2600(22)00170-9 |
| _version_ | 1784701778337464320 |
|---|---|
| author | Tartof, Sara Y Slezak, Jeff M Puzniak, Laura Hong, Vennis Xie, Fagen Ackerson, Bradley K Valluri, Srinivas R Jodar, Luis McLaughlin, John M. |
| author_facet | Tartof, Sara Y Slezak, Jeff M Puzniak, Laura Hong, Vennis Xie, Fagen Ackerson, Bradley K Valluri, Srinivas R Jodar, Luis McLaughlin, John M. |
| author_sort | Tartof, Sara Y |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9075856 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90758562022-05-09 Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants Tartof, Sara Y Slezak, Jeff M Puzniak, Laura Hong, Vennis Xie, Fagen Ackerson, Bradley K Valluri, Srinivas R Jodar, Luis McLaughlin, John M. Lancet Respir Med Correspondence Elsevier Ltd. 2022-07 2022-05-06 /pmc/articles/PMC9075856/ /pubmed/35533699 http://dx.doi.org/10.1016/S2213-2600(22)00170-9 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Tartof, Sara Y Slezak, Jeff M Puzniak, Laura Hong, Vennis Xie, Fagen Ackerson, Bradley K Valluri, Srinivas R Jodar, Luis McLaughlin, John M. Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants |
| title | Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants |
| title_full | Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants |
| title_fullStr | Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants |
| title_full_unstemmed | Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants |
| title_short | Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants |
| title_sort | immunocompromise and durability of bnt162b2 vaccine against severe outcomes due to omicron and delta variants |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075856/ https://www.ncbi.nlm.nih.gov/pubmed/35533699 http://dx.doi.org/10.1016/S2213-2600(22)00170-9 |
| work_keys_str_mv | AT tartofsaray immunocompromiseanddurabilityofbnt162b2vaccineagainstsevereoutcomesduetoomicronanddeltavariants AT slezakjeffm immunocompromiseanddurabilityofbnt162b2vaccineagainstsevereoutcomesduetoomicronanddeltavariants AT puzniaklaura immunocompromiseanddurabilityofbnt162b2vaccineagainstsevereoutcomesduetoomicronanddeltavariants AT hongvennis immunocompromiseanddurabilityofbnt162b2vaccineagainstsevereoutcomesduetoomicronanddeltavariants AT xiefagen immunocompromiseanddurabilityofbnt162b2vaccineagainstsevereoutcomesduetoomicronanddeltavariants AT ackersonbradleyk immunocompromiseanddurabilityofbnt162b2vaccineagainstsevereoutcomesduetoomicronanddeltavariants AT vallurisrinivasr immunocompromiseanddurabilityofbnt162b2vaccineagainstsevereoutcomesduetoomicronanddeltavariants AT jodarluis immunocompromiseanddurabilityofbnt162b2vaccineagainstsevereoutcomesduetoomicronanddeltavariants AT mclaughlinjohnm immunocompromiseanddurabilityofbnt162b2vaccineagainstsevereoutcomesduetoomicronanddeltavariants |